Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCMEL09109

Title

Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

Principal Investigator(s)

Jeffrey Sosman

Details

  • Protocol No. VICCMEL09109
  • Open Date: 06/03/2010
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: To procure and maintain a repository of left-over human biological specimens, while also protecting the confidentiality of individuals donating to the repository in the course of their medical care. To articulate and implement criteria allowing the acquisition, storage, research use of such specimens, and their use for clinical testing to inform the assignment of therapy.
  • Disease Sites: Melanoma
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01205815
  • Secondary Protocol No: Not Specified

Description

The purpose of this study is to test melanoma tumor to see if it has specific genetic markers (special characteristics) of interest. These tests may provide information about the tumor that could help patients make treatment plans in the future.

Eligibility

Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Criteria

Inclusion criteria
• Pathologically-proven diagnosis of melanoma.
• Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.
Exclusion criteria
• Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.
• Any patient unable or unwilling to provide consent.